![Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend [zydRGYwbdTp]](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-5469158-150x150.jpg "Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend [zydRGYwbdTp] 1")
GLP-1 Drugs, Semaglutide, and the Future of Alcohol Addiction Treatment
GLP-1 receptor agonists for alcohol use disorder are attracting growing scientific interest as potential tools for reducing alcohol consumption and relapse risk. This review examines preclinical evidence, observational studies, and randomized controlled…
Weight Loss, Metabolic Health, and Psychiatric Safety
Semaglutide for schizophrenia weight gain is emerging as a focused metabolic strategy for patients whose antipsychotic treatment has created serious weight and glucose burden. This Evidence Watch review examines RCT meta-analysis data showing meaningful…
Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic Patients
A study comparing Tirzepatide to Semaglutide in diabetic CABG patients found significant benefits for cerebrovascular and cardiovascular outcomes, reducing mortality and complications.
Dysesthesia associated with GLP-1 agonist therapies- data-mining analysis
A study reveals that GLP-1 agonists like semaglutide are linked to significant signals for hyperesthesia, dysesthesia, and burning sensation. These reactions are dose-dependent and can recur upon rechallenge.
SemaGBA- A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis
The SemaGBA model simulates semaglutide's effects on metabolic and neural pathways, providing insights into its mechanisms of action.
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.
Hair Shedding, Weight Loss, and GLP-1 Therapy: Separating Signal from Speculation
GLP-1 hair loss risk has become a growing concern as semaglutide and tirzepatide use expands. A large propensity-matched cohort study found significantly higher rates of nonscarring hair loss among users of both medications compared with metformin. The…
Semaglutide Weight Loss: 28% Results in Early Responders
Higher-dose semaglutide weight loss shows promising results with approximately 28% reduction in early responders. This trial highlights the importance of dose escalation in obesity treatment. Understanding early response helps optimize therapy with…
Clinical Evidence for Semaglutide Efficacy in Older Adults
Semaglutide efficacy older adults is supported by recent pooled clinical trial data showing meaningful weight loss and safety in patients over 65. This evidence fills a critical gap for prescribers considering GLP-1 receptor agonists in older…
GLP-1 Receptor Agonists: Clinical Evidence and Safety
Semaglutide weight loss management is supported by clinical evidence demonstrating its benefits and safety profile. GLP-1 receptor agonists like semaglutide aid in appetite regulation and metabolic health. Understanding the clinical evidence is essential…